Cantex has two product candidates in clinical development:
Dicopp®:
- Blocks mechanisms critical to initiation and propagation of lung and systemic inflammation associated with COVID-19 infection and other lung diseases
- Blocks mechanisms essential for cancer cell survival
- Phase 2 trials in 2021
- “Long –Haulers”: persistent and disabling myalgic encephalitis/chronic fatigue syndrome-like symptoms of COVID-19 infection after virus has cleared
- Newly diagnosed COVID-19 infection to accelerate recovery and prevent need for hospitalization
- Relapsed/refractory myeloma
- Cantex owns issued and pending intellectual property for Dicopp®
- Dicopp® is a 505(b)(2)product
DSTAT:
- Licensed to Chimerix in July 2019. Continued participation in development via Joint Development Committee
- Key deal terms:
- $30 million upfront
- 10 million shares of Chimerix common stock
- Payments for achieving sales milestones and regulatory approvals totaling $587.5 million
- Tiered double-digit royalties on net sales
- Completed randomized Phase 2 study in acute myeloid leukemia (AML) suggested DSTAT + “7+3” improves event-free and relapse-free survival as well as overall survival without additive toxicity
- Phase 3 clinical trial in AML to begin in early 2021
- Pre-clinical data indicates that DSTAT may reduce inflammation, decrease immune cell infiltration and prevent and treat coagulation disorders associated with acute lung injury
- Phase 2/3 study of DSTAT in COVID-19 associated acute lung injury is in progress